Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory
New Distribution Agreement paves the way for expanded regional access to LucentAD® Complete
LucentAD Complete from
“Sherman Abrams Lab understands the patient's needs and shares our commitment to expanding access to advanced diagnostics,” said
According to the Alzheimer’s Association, more than 676,800 people aged 65 and older are already living with Alzheimer’s disease across NY, NJ, and CT. The new distribution agreement is aimed at expanding access to blood-based testing for people who exhibit some signs or are at risk of Alzheimer's Disease although they have not yet been formally diagnosed with unmet clinical needs.
“We are excited to partner with
Through the exclusive arrangement, Sherman Abrams will offer LucentAD Complete testing to its extensive network of referring physicians throughout Metro NY/NJ region, expanding access to innovative blood-based Alzheimer's testing and supporting earlier detection and more informed patient care.
To learn more about LucentAD Complete, visit www.lucentdiagnostics.com. To learn more about
About
About Sherman Abrams
Established in 1964, Sherman Abrams Labs is Brooklyn's foremost full service clinical and anatomic pathology laboratory. Community based, it provides laboratory service to its patients, physician offices, nursing homes, adult homes, hospitals, rehabilitation centers, dialysis centers and home-bound patients. Sherman Abrams continues to grow through its focus on offering personalized health care, and heavy investment in state-of-the-art technology and its employees. For more information, please visit https://www.shermanabrams.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116941665/en/
Quanterix Media Contact:
media@quanterix.com
Investor Relations Contact:
Ir@quanterix.com
Source: Quanterix Corporation